Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Xeljanz

- PMLiVE

Merck wins speedy FDA review for 15-valent pneumococcal vaccine

Pfizer's rival 20-valent candidate was granted priority review in December 2020

- PMLiVE

Pfizer makes first investments through ‘breakthrough growth’ fund

Pharma giant invested $120m in four biotechs in the second half of 2020

- PMLiVE

BioNTech boosts COVID-19 vaccine capacity and aims to deliver 2 billion doses in 2021

Company will also publish data on vaccine's efficacy against new variants soon

- PMLiVE

Pfizer/BioNTech vaccine shown to be effective against new COVID-19 variants

Vaccine tested against variants discovered in the UK and South Africa

- PMLiVE

Pfizer introduces new logo in a ‘shift from commerce to science’

First major rebranding in 70 years for pharma giant

- PMLiVE

Roche’s tiragolumab plus Tecentriq combo wins FDA breakthrough therapy designation

Swiss pharma is aiming for approval in first-line NSCLC

- PMLiVE

WHO advises both doses of Pfizer/BioNTech’s COVID-19 vaccine within a 21-28 day schedule

Recommendations made by the WHO's Strategic Advisory Group of Experts on Immunization

- PMLiVE

FDA will not alter dosing schedules for authorised COVID-19 vaccines

Time period between first and second vaccines has been extended in the UK

- PMLiVE

Inovio plans late-stage COVID-19 vaccine study in second quarter 2021

FDA had placed trial on a temporary hold in September 2020

- PMLiVE

Pfizer/BioNTech to offer COVID-19 vaccine to placebo recipients

Only those trial participants who are currently eligible under the EUA will be offered the vaccine

- PMLiVE

Pfizer, Sanofi and others set to increase US drug prices in 2021

Pressure from COVID-19 restrictions leads to drug price increases

- PMLiVE

COVID-19 vaccine developers respond to new strain

Pfizer, Moderna and AstraZeneca suggest their respective vaccines should remain effective

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links